<p>InflaRx (NASDAQ:IFRX - 獲取免費報告) 將在 8 月 8 日星期四市場開盤前公佈其財報。分析師預計公司將公佈本季度每股虧損$0.21 的收益。</p>
<p>InflaRx (NASDAQ:IFRX - 獲取免費報告) 上次公佈財報是在 5 月 8 日星期三。公司報告本季度每股虧損$0.19，超過分析師預期的$0.05。本季度公司營收為$0.04 百萬美元，低於分析師預期的$1.76 百萬美元。平均而言，分析師預計 InflaRx 本財年每股虧損$-1，下一財年每股虧損$-1。</p>
<h2>InflaRx 價格表現</h2>
<p>週五，納斯達克股票代碼為 IFRX 的股票下跌$0.06，收於$1.46。公司交易量為 7,559 股，低於平均交易量 191,815 股。該公司市值為$85.96 百萬美元，市盈率為-1.95，貝塔係數為 1.58。公司的 50 天簡單移動平均線為$1.57，200 天簡單移動平均線為$1.54。InflaRx 的 12 個月最低價為$1.14，最高價為$4.30。</p>
<h2>華爾街分析師觀點</h2>
<p>另外，HC Wainwright 重申了對 InflaRx 的 “買入” 評級，並設定了 6 月 24 日星期一的$8.00 目標價。</p>
<p><strong>查看我們關於 IFRX 的最新股票報告</strong></p>
<h2>關於 InflaRx (獲取免費報告)</h2>
<p>InflaRx N.V.是一家臨牀階段的生物製藥公司，利用 C5a 技術在德國和美國發現和開發抑制劑。該公司的 C5a 是一種參與多種自身免疫和其他炎症性疾病進展的炎症介質。其主要產品候選藥物是 vilobelimab，一種新型靜脈注射的首創抗 C5a 單克隆抗體，已完成用於治療汗腺炎的第三期臨牀試驗，這是一種罕見的慢性致殘性全身性炎症性皮膚病；用於治療抗中性粒細胞胞漿抗體相關血管炎，這是一種罕見且危及生命的自身免疫疾病，目前處於第二期試驗階段；用於治療化膿性壞疽，一種慢性炎症性皮膚疾病，目前處於第二期 a 探索性研究階段；以及用於治療 PD-1/PD-L1 抑制劑耐藥/難治的局部晚期或轉移性鱗狀細胞癌，目前處於第二期臨牀開發階段。</p>
<h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票比 InflaRx 更好</li>
<li>如何投資小市值股票</li>
<li>亞馬遜股票在 AI 泡沫破裂後有望強勁反彈</li>
<li>投資高市盈率成長股</li>
<li>殼牌股票：石油和天然氣巨頭致力於回購和股息</li>
<li>頂尖生物科技股票：探索創新機會</li>
<li>雪佛龍股價下跌，盈利不及預期突顯合併不確定性</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA"/></p>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經經過 MarketBeat 的編輯團隊審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 時間不多了-6 月 25 日截止！（來自 Paradigm Press）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx"/></p>
<h2>現在是否值得投資$1,000 購買 InflaRx?</h2>
<p>在考慮 InflaRx 之前，您會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 InflaRx 不在名單上。</p>
<p>儘管 InflaRx 目前在分析師中有 “強烈買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

IFRX

<p>InflaRx（納斯達克股票代碼：IFRX）將於 8 月 8 日星期四發佈其季度財報。分析師預計該季度每股盈利為（$0.21）。InflaRx 是一家臨牀階段的生物製藥公司，致力於開發用於炎症性疾病的抑制劑。其主力產品候選藥物是 vilobelimab，一種新型抗 C5a 單克隆抗體。該公司上一次在五月份報告的每股盈利為（$0.19），超過了分析師的預期。InflaRx 的市值為 8,596 萬美元</p>

<p>InflaRx (NASDAQ:IFRX - Get Free Report) will be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.</p>
<div class="lb-trans"><p>InflaRx (NASDAQ:IFRX - 獲取免費報告) 將在 8 月 8 日星期四市場開盤前公佈其財報。分析師預計公司將公佈本季度每股虧損$0.21 的收益。</p>
</div><p>InflaRx (NASDAQ:IFRX - Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.05. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $1.76 million. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>InflaRx (NASDAQ:IFRX - 獲取免費報告) 上次公佈財報是在 5 月 8 日星期三。公司報告本季度每股虧損$0.19，超過分析師預期的$0.05。本季度公司營收為$0.04 百萬美元，低於分析師預期的$1.76 百萬美元。平均而言，分析師預計 InflaRx 本財年每股虧損$-1，下一財年每股虧損$-1。</p>
</div><h2>InflaRx Price Performance</h2>
<div class="lb-trans"><h2>InflaRx 價格表現</h2>
</div><p>Shares of NASDAQ:IFRX traded down $0.06 during trading on Friday, reaching $1.46. 7,559 shares of the company were exchanged, compared to its average volume of 191,815. The firm has a market capitalization of $85.96 million, a PE ratio of -1.95 and a beta of 1.58. The business's fifty day simple moving average is $1.57 and its 200-day simple moving average is $1.54. InflaRx has a 12-month low of $1.14 and a 12-month high of $4.30.</p>
<div class="lb-trans"><p>週五，納斯達克股票代碼為 IFRX 的股票下跌$0.06，收於$1.46。公司交易量為 7,559 股，低於平均交易量 191,815 股。該公司市值為$85.96 百萬美元，市盈率為-1.95，貝塔係數為 1.58。公司的 50 天簡單移動平均線為$1.57，200 天簡單移動平均線為$1.54。InflaRx 的 12 個月最低價為$1.14，最高價為$4.30。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $8.00 target price on shares of InflaRx in a research report on Monday, June 24th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 重申了對 InflaRx 的 “買入” 評級，並設定了 6 月 24 日星期一的$8.00 目標價。</p>
</div><p><strong>Check Out Our Latest Stock Report on IFRX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 IFRX 的最新股票報告</strong></p>
</div><h2>About InflaRx (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 InflaRx (獲取免費報告)</h2>
</div><p>InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.</p>
<div class="lb-trans"><p>InflaRx N.V.是一家臨牀階段的生物製藥公司，利用 C5a 技術在德國和美國發現和開發抑制劑。該公司的 C5a 是一種參與多種自身免疫和其他炎症性疾病進展的炎症介質。其主要產品候選藥物是 vilobelimab，一種新型靜脈注射的首創抗 C5a 單克隆抗體，已完成用於治療汗腺炎的第三期臨牀試驗，這是一種罕見的慢性致殘性全身性炎症性皮膚病；用於治療抗中性粒細胞胞漿抗體相關血管炎，這是一種罕見且危及生命的自身免疫疾病，目前處於第二期試驗階段；用於治療化膿性壞疽，一種慢性炎症性皮膚疾病，目前處於第二期 a 探索性研究階段；以及用於治療 PD-1/PD-L1 抑制劑耐藥/難治的局部晚期或轉移性鱗狀細胞癌，目前處於第二期臨牀開發階段。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than InflaRx</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Shell Stock: Oil &amp; Gas Giant Committed to Buybacks and Dividends</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票比 InflaRx 更好</li>
<li>如何投資小市值股票</li>
<li>亞馬遜股票在 AI 泡沫破裂後有望強勁反彈</li>
<li>投資高市盈率成長股</li>
<li>殼牌股票：石油和天然氣巨頭致力於回購和股息</li>
<li>頂尖生物科技股票：探索創新機會</li>
<li>雪佛龍股價下跌，盈利不及預期突顯合併不確定性</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IFRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經經過 MarketBeat 的編輯團隊審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 時間不多了-6 月 25 日截止！（來自 Paradigm Press）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDEx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9011&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in InflaRx right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 購買 InflaRx?</h2>
</div><p>Before you consider InflaRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 InflaRx 之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 InflaRx 不在名單上。</p>
</div><p>While InflaRx currently has a &#34;Strong Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 InflaRx 目前在分析師中有 “強烈買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

InflaRx (IFRX) 將於週四公佈季度財報